瑞替普酶与低相对分子质量肝素早期溶栓治疗急性心肌梗死的对比研究

目的 对比瑞替普酶联合低相对分子质量肝素（LMWH）治疗急性心肌梗死（AMI）患者的疗效和安全性.方法 选取2008年6月～2013年1月在本院治疗的AMI住院患者131例,随机分为A组（瑞替普酶组,67例）和B组（对照组,64例）.两组在使用LMWH的基础上,A组使用瑞替普酶;B组使用生理盐水作为对照.观察对比两组的疗效和并发症发生率.结果 两组不良反应和并发症的发生率差异无统计学意义（P＞0.05）.A组的冠脉再通率59例（86.7%）与B组的47例（73.4%）比较明显增加,差异有统计学意义（χ2=4.532,P=0.033,P＜0.05）.结论 瑞替普酶联合LMWH治疗AMI是安全有效的,较单纯使用LMWH疗效明显.

Comparative the Effect of Thrombolytic Therapy using Rhteplase and Low Molecular Weight Heparin in Patients with Acute Myocardial Infarction

Objective To contrast the effect of thrombolytic therapy using rhteplase and low molecular weight heparin （LMWH）in patients with acute myocardial infarction （AMI）. Methods 131 patients with AMI asmitted in our department from 2008. June ~ 2013. Jcnuory, randomly divided into group A （reteplase the gen- eral enzyme group,67 cases） ,and group B（ control group,64 cases）. Based on the LMWH in the two groups, reteplase was used in group A and saline was used in group B. Efficacy and complication rates of the two groups were compared. Results It is no significant difference between the two groups about the incidence of complications （P 〉 0.05 ）. Compared with group B 47 cases （73.4%）, group A 59 cases （ 86.7% ） coronary recanalization rate was increased,the difference was statistically significant difference（ X2 =4. 532 ,P = 0. 033, P 〈 0.05 ）. Conclusion Rhaetian the general enzyme combined with LMWH in the treatment of AMI event is safe and effective,than the simple use of LMWH is effective.